- Legislation Introduced to Codify Stem Cell Rules
- Commissioner Enhances FDA’s Commitment to Personalized Medicine
- Perfecting Policy on Stem Cells
- NIH and FDA Aim to Retool Regulatory Science
- DOE Leads Federal Funding for a Regional Innovation Cluster
- Certainty on the Science of Climate Change
- They’re Not Perfect Cells, But They’re Model Cells
- Genomic Medicine on the March
- President’s Budget Aims to Recharge Regional Innovation
- Event: The Science of Climate Change
- Progress in Bioethics
- The Top Science Progress Features of 2009
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
Big Bucks for Science of All Sizes
Francis Collins took the reigns of the National Institutes of Health as director in August. Shortly thereafter, he invited a Kathy Hudson, a former colleague from the National Human Genome Research Institute, to serve as his chief of staff, a new role within the director’s office. This week, they each shared some of their thinking on the direction of the NIH with interviews in the New England Journal of Medicine and The Scientist, respectively.
Hudson, who co-authored a popular SP article on how to engage the scientific community with the American public, was formerly head of the Johns Hopkins Genetics & Public Policy Center. She told The Scientist that talks were ongoing about how to manage the additional $10.4 billion dollars in NIH funding provided by the American Recovery and Reinvestment Act, but the Institutes are wasting no time in getting money to researchers. “Five billion dollars are going out the door this month,” she said.
In talking to NEJM, Collins acknowledged the tension between supporting “big science” projects like the Human Genome Research Project and investigator-driven studies. He offered this synthesis: “The foundation of advances in biomedical research will continue to be the bright ideas of individual investigators, but if they are empowered by tools and databases and technologies that big science has made available, then we can go faster,” he said.
Collins also said that the question of what happens when the ARRA funds run out weighs heavy, saying: “There is much discussion about the NIH falling off a cliff. Scientific research is not a 100-yard dash. It is a marathon. Two years is way too short to take a cool idea and develop it to some sort of end point.”
Ensuring a smooth funding transition in 2010 should be a priority for Congress, and that process begins now, by ending the five-year streak of flat baseline funding for the NIH. There’s no shortage of good science to fund, and biomedical research creates good jobs as it improves the health of Americans and the economy.
Comments on this article
